<unk>  is a antineoplasic agent that is FDA approved for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.
Cabazitaxel
Paclitaxel
Zorubicin
Taxane
Stibine
Doxorubicin hydrochloride
Ifosfamide
Idoxuridine